Valuation: Malin Corporation Plc

Market Cap 29.48M 33.84M 27.83M 25.28M 47.35M 3.25B 47.51M 333M 129M 1.65B 127M 124M 5.31B P/E 2024 *
-
P/E 2025 -8.37x
Enterprise Value 16.58M 19.03M 15.65M 14.21M 26.63M 1.83B 26.72M 187M 72.32M 929M 71.48M 69.89M 2.99B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
63.83%
Yield 2024 *
-
Yield 2025 -
1 day-2.86%
1 week-2.86%
Current month-2.86%
1 month-2.86%
3 months-4.90%
6 months-10.53%
Current year-11.69%
1 week 6.8
Extreme 6.8
7
1 month 6.8
Extreme 6.8
7
Current year 6.8
Extreme 6.8
8.45
1 year 6.8
Extreme 6.8
9.3
3 years 3.84
Extreme 3.84
10.4
5 years 3.59
Extreme 3.59
10.4
10 years 1.4
Extreme 1.4
13.85
Manager TitleAgeSince
Director of Finance/CFO 56 2022-04-30
Director TitleAgeSince
Chairman 73 2019-08-01
Director/Board Member 67 2018-07-15
Director/Board Member 63 2018-07-15
Date Insider Type Main position Quantity % Market Cap. Importance
6/2/26 Exercice 10,307 0.2382%
5/28/25 Exercice

Chief Executive Officer

5,746 0.1328%
4/7/25 Sell

Director

11,075 0.2560%
Change 5-day change 1-year change 3-year change Capi.($)
-2.86%-2.86%-13.38%+47.83% 33.81M
+0.04%+3.34%+53.32%+100.52% 1,028B
-0.09%+1.66%+53.24%+66.45% 651B
-0.02%+2.66%+18.65%+71.97% 466B
-1.22%+3.66%+34.59%+38.81% 346B
-0.79%+2.73%+17.73%+25.11% 266B
+0.58%+6.76%+10.58%+17.75% 259B
+1.55%+2.20%+35.12%+45.91% 208B
+0.79%+1.84%-27.55%-56.48% 191B
-0.52%+4.45%+31.57%+98.11% 186B
Average -0.25%+2.64%+21.39%+45.60% 360.18B
Weighted average by Cap. -0.04%+3.09%+34.84%+61.60%

Financials

2024 2025
Net sales - -
Net income - -6.9M -7.92M -6.51M -5.92M -11.08M -760M -11.12M -77.85M -30.1M -387M -29.75M -29.09M -1.24B
Net Debt -62.1M -71.3M -58.62M -53.25M -99.74M -6.84B -100M -701M -271M -3.48B -268M -262M -11.2B -12.9M -14.81M -12.18M -11.06M -20.72M -1.42B -20.79M -146M -56.27M -723M -55.62M -54.38M -2.33B
Logo Malin Corporation Plc
Malin Corporation Plc is a company investing in and supporting highly innovative life sciences companies developing exceptional science and technology to deliver transformative outcomes for patients and create significant value for shareholders. Its purpose is to create shareholder value through the application of long-term capital and strategic support to its investee companies to enable them to reach their value potential.
Employees
2
Date Price Change Volume
26-09-18 €6.800 -2.86% 141
26-09-17 €7.000 0.00% 0
26-09-16 €7.000 0.00% 0
26-09-15 €7.000 0.00% 1
26-09-14 €7.000 0.00% 0
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
6.800EUR
Average target price
15.50EUR
Spread / Average Target
+127.94%
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!